U.S. health advisers said GlaxoSmithKline Plc's diabetes drug Avandia raised a heart attack concern compared with diabetes drugs in other classes and a rival drug in the same class.
U.S. health advisers said GlaxoSmithKline Plc's diabetes drug Avandia raised a heart attack concern compared with diabetes drugs in other classes and a rival drug in the same class.
U.S. advisers neared a vote on whether a GlaxoSmithKline Plc diabetes drug carries too much heart risk to stay on the market, hearing final conflicting pleas Wednesday from a patient and a public health advocate.
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
GlaxoSmithKline Plc has agreed to pay $460 million to settle thousands of lawsuits over its Avandia diabetes pill, Bloomberg reported on Tuesday, on the eve of a crucial vote by U.S. experts on whether the pill should be withdrawn due to heart risks.
GlaxoSmithKline Plc insisted its diabetes pill Avandia was safe as U.S. advisers began a two-day meeting to consider if the medicine is too dangerous to stay on the market.
U.S. advisers began weighing the fate of GlaxoSmithKline Plc's diabetes pill Avandia on Tuesday at a two-day meeting that will consider if the medicine is too dangerous to stay on the market.
A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
Lawyers for patients who say they have been harmed by GlaxoSmithKline Plc's Avandia say critical data is still under wraps even as a U.S. advisory panel prepares to weigh the fate of the controversial diabetes drug.
Two recent studies linking the diabetes drug Avandia to heart ailments prompted the U.S. Food and Drug Administration (FDA) to consider withdrawing it from the market.
GlaxoSmithKline Plc's diabetes pill Avandia came under intense scrutiny on both sides of the Atlantic on Friday, leaving the drug's future uncertain as its maker battles a growing tide of lawsuits.
European regulators are launching a new probe into the safety of GlaxoSmithKline Plc's diabetes pill Avandia, adding to pressure on a medicine that already faces a grilling from U.S. experts next week.
A European Union court backed an EU antitrust decision against Anglo-Swedish drugmaker AstraZeneca Thursday, lending weight to a regulatory crackdown on firms blocking cheaper drugs coming to market.
The 10-year-old Human Genome Project has only just begun to bring to fruition its promise to transform medicine, its founders said on Thursday.
Two extra mutations set the stage for the seasonal influenza virus to evolve into a form that now resists three of the four drugs designed to fight it, researchers reported on Thursday.
Abbott Laboratories Inc will pay $3.72 billion to acquire the branded generics business of India's Piramal Healthcare , as global drugmakers look to boost their presence in emerging markets.
Abbott Laboratories Inc will pay $3.72 billion to acquire India's Piramal Healthcare's pharmaceutical solutions business, as global drugmakers look to boost their presence in emerging markets.
(Reuters) - The World Health Organization conceded shortcomings on Monday in its handling of the H1N1 swine flu pandemic, including a failure to communicate uncertainties about the new virus as it swept around the globe.
(Reuters) - Drugmakers Pfizer and GlaxoSmithKline signed a landmark 10-year deal on Tuesday to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations.
Two U.S. drug safety reviewers have recommended that GlaxoSmithKline PLC's diabetes drug Avandia be pulled from the market after concluding it is more dangerous to the heart than a rival medicine, according to documents released on Saturday.
The composition of the vaccine, announced at the end of a closed-door four-day meeting of influenza experts that is closely followed by the world's vaccine makers, means governments that have stockpiled doses of H1N1 swine flu vaccine may now use them for part of the seasonal flu vaccine mix.
